MILTON ESSEX S.A.
0.55
PLN
0.00
(0.00%)
ISIN
PLMLTNE00013
Return %
Stock
S&P 500
1Y
-38.20
14.20
3Y
-15.38
81.12
5Y
-62.59
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Jacek Bernard Stepien
- Full Time Employees
- 3
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Warsaw Poland
- IPO Date
- Dec 18, 2020
- Website
- miltonessex.eu
- Similar Companies
- Business
- MILTON ESSEX S.A. is a Poland-based medical technology and biotechnology company that develops, manufactures, and commercializes artificial intelligence-driven diagnostic systems, optoelectronic medical devices, and advanced cellular biotherapeutics. The company operates primarily across two core business segments: Medical Technology (Med-Tech) and Veterinary Biotechnology (Bio-Tech). In its Med-Tech segment, the company offers SkinSENS, an automated, non-invasive diagnostic medical platform utilizing long-wave infrared (LWIR) hyperspectral imaging and proprietary SkinLogic artificial intelligence algorithms for objective skin allergy assessment; Allergoscope, an integrated digital allergy diagnostic solution combining clinical anamnesis with computerized test interpretation; and FaceCOV (also marketed as ActiveSCAN), a contactless access control and monitoring system featuring automated thermographic screening, biometric verification, and documentation validation. In its Biotechnology segment, operated through its consolidated subsidiary Sanford Biotech Sp. z o.o., the company develops veterinary advanced therapy medicinal products (VET-ATMP) based on mesenchymal stem cells (MSCs) and targeted biological therapies; these include therapeutic solutions for bovine mastitis in dairy cattle as well as treatments for degenerative and inflammatory musculoskeletal disorders in horses, dogs, and companion animals. The company targets healthcare institutions, allergy and dermatology clinics, corporate and security facilities, and veterinary practices across Poland and international European markets. In recent developments, Milton Essex executed a major strategic expansion transforming into an integrated bio-medical group through the strategic partnership and consolidation of Sanford Biotech Sp. z o.o., establishing a dedicated veterinary biotechnology division. The company has actively expanded capital allocations to accelerate clinical research and preclinical development for its VET-ATMP portfolio, while advancing commercialization partnerships and regulatory compliance processes for European medical device certification of its SkinSENS platform. Founded in 2015, Milton Essex S.A. is headquartered in Warsaw, Poland, and trades on the NewConnect market of the Warsaw Stock Exchange under the ticker symbol MTN.